Methods and Pharmaceutical Compositions for Treating Candida Auris in Blood

ChangeBridge: EPO Bulletin - Therapeutics (A61P)

Published March 25th, 2026

Detected April 1st, 2026

Summary

The European Patent Office published patent EP3727393A2 to CorMedix Inc. for methods and pharmaceutical compositions used to treat Candida Auris in blood. The patent names inventors DiLucciO and Reidenberg and covers designated states across Europe including Germany, France, UK, Italy, Spain, and 24 other countries.

View original document View source feed page

What changed

The EPO published CorMedix Inc.'s patent EP3727393A2 for treating Candida Auris fungal infections in blood using pharmaceutical compositions. The patent covers compositions containing compounds classified under A61K 31/549, A61K 47/12, A61K 47/36, A61L 27/54, and A61P 31/10. The designated states include all 27 EU member states plus Norway, Switzerland, Turkey, and other European countries.

Pharmaceutical companies and healthcare providers developing antifungal blood treatments should review this patent for potential licensing needs or to assess Freedom to Operate. The patent establishes CorMedix's intellectual property rights in this therapeutic area and may affect competitive landscape for Candida Auris treatment development in European markets.

Source document (simplified)

← EPO Patent Bulletin

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANDIDA AURIS IN BLOOD

Publication EP3727393A2 Kind: A2 Mar 25, 2026

Applicants

CorMedix Inc.

Inventors

DILUCCIO, Robert, REIDENBERG, Bruce

IPC Classifications

A61K 31/549 20060101AFI20210831BHEP A61K 47/12 20060101ALI20210831BHEP A61K 47/36 20060101ALI20210831BHEP A61L 27/54 20060101ALI20210831BHEP A61P 31/10 20060101ALI20210831BHEP A61K 9/00 20060101ALI20210831BHEP A61K 9/51 20060101ALI20210831BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →